Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

While it's possible for some DMTs to be infused at home, most people choose to come to the RUSH Multiple Sclerosis Center. The oldest and largest MS treatment center in the region, the center has ...

A groundbreaking study has unveiled a critical issue of therapeutic inertia in treating women with multiple sclerosis (MS ... of initiating or intensifying treatment for a medical condition ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

The research, presented today at ECTRIMS 2024, is the result of efforts by the Alliance for Research in Hispanic MS (ARHMS) Consortium and is the first large-scale study to identify ancestry-specific ...

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...